REG - hVIVO PLC - £6m Influenza HCT contract signed

hVIVOAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260507:nRSG3169Da&default-theme=true

RNS Number : 3169D  hVIVO PLC  07 May 2026

 

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

£6m Influenza HCT contract signed with clinical-stage biopharmaceutical
company

 

Human Challenge study to test a monoclonal antibody; with revenue to be
recognised across 2026 & 2027

 

London, UK - 7 May 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service
international clinical development partner and the world leader in human
challenge trials, announces that it has signed a £6 million Clinical Trial
Agreement ("CTA") to conduct a human challenge (HCT) trial on behalf of a
clinical-stage biopharmaceutical company developing novel therapies for
respiratory viral diseases. The trial will evaluate the monoclonal antibody
using the hVIVO Influenza Human Challenge Study Model.

 

This will be a randomised, double-blinded placebo-controlled trial planned to
take place at the Company's specialist state-of-the-art quarantine facilities
in Canary Wharf. Healthy participants will be recruited through the Company's
participant recruitment arm, FluCamp (http://www.flucamp.com/) , and all lab
work associated with the efficacy analysis for the study will be conducted by
hVIVO's own specialist virology laboratory in Canary Wharf.

 

The study is expected to commence in 2026, with revenue recognised in 2026 and
2027. This contract, along with others recently announced, provides a
significant step change to revenue visibility in 2026.

 

Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "hVIVO's ability to
deliver integrated recruitment, clinical trials and specialist virology
analytics enables our clients to evaluate innovative assets rapidly and
rigorously, delivering clear, value-generating data. This study reflects the
strength of our end‑to‑end offering and our continued focus on supporting
partners developing differentiated solutions for influenza prevention."

 

Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, added: "Our Influenza
Human Challenge Study Model is specifically designed to characterise viral
kinetics and host responses, enabling effective early evaluation of the
clinical and virological impact of novel drugs. Seasonal influenza remains a
significant burden for global healthcare systems and hVIVO is proud to help
speed up the development of new therapies that are vital to reducing the
severity of yearly outbreaks."

 

Seasonal influenza causes significant morbidity and mortality each year, with
an estimated 1 billion cases per year, 3-5 million severe cases and 290,000 -
650,000 deaths per year. To date, hVIVO has inoculated >5,000 healthy
participants across 2,477 influenza, RSV and other viral HCTs, and has also
helped accelerate the development of several antiviral and vaccine candidates
for both Big Pharma and biotechnology clients through its consulting,
laboratory and clinical trial services.

 

For further information please contact:

 

 hVIVO plc                                                                           +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                                                      +44 (0)20 7220 0500
 Geoff Nash, Callum Davidson

Trisyia Jamaludin, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                                                            +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                                                     +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 ICR Healthcare (Financial PR & IR)                                                  hVIVO@icrhealthcare.com

 Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson

 

Notes to Editors

 

hVIVO plc (https://hvivo.com/) (AIM: HVO) is a purpose-built, full-service
international clinical development partner and the global leader in human
challenge trials, serving seven of the world's ten largest biopharma
companies.

 

The Company has an end-to-end platform designed to bring important medicines
to patients faster: spanning preclinical strategy, first‑in‑human studies,
Phase II patient trials and specialist laboratory services, delivered through
a large participant database, wholly owned sites and laboratories across the
UK and Germany.

 

With a combined Group heritage of more than 100 years, hVIVO delivers an
accelerated pathway to clinical proof-of-concept through four integrated
service lines: Consulting, Clinical Trials, Human Challenge Trials, and
Laboratories.

 

·    Consulting
(https://www.hvivo.com/solutions/drug-development-consulting) provides
expert-led preclinical and clinical strategy, encompassing non-clinical,
clinical, CMC, pharmacokinetics, data management, biostatistics, and
regulatory support to guide trial design, execution, and interpretation.

·    Clinical Trials (https://www.hvivo.com/solutions/clinical/) offers
Phase I/II CRO services, Phase II/III site services across the UK and Germany,
and specialist recruitment through FluCamp (http://www.flucamp.com/) ,
Europe's largest recruitment database.

·    Human Challenge Trials
(https://www.hvivo.com/solutions/human-challenge) leverages hVIVO's
state-of-the-art quarantine facility in London - the largest of its kind
worldwide - to deliver fast, controlled, high-quality efficacy data through
guaranteed viral exposure.

·    Laboratories (https://www.hvivo.com/solutions/laboratory) provides
cutting-edge virology and immunology laboratory services, including biobanking
and sample storage, supporting both challenge trials and standalone client
studies.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTAKABPOBKDPPK



            Copyright 2019 Regulatory News Service, all rights reserved